ReviewUrologie (Heidelberg, Germany)2023
[New S3 guideline prostate cancer 2021 (version 6.2)-What has changed in advanced prostate cancer?]
Review in Urologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Demonstration of anatomical and technical details of robotic laparoscopic radical prostatectomy as described in the current literature.Frontiers in surgery · 2026Article
- Prostate cancer treatment with electrochemotherapy (ECT): safety, efficacy and clinical experience in 144 patients.Radiology and oncology · 2025Article
- [Surgical techniques to improve continence after robot-assisted laparoscopic radical prostatectomy based on video-anatomy-a review].Urologie (Heidelberg, Germany) · 2025Review
- Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe.Future oncology (London, England) · 2025Article
- PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.EJNMMI reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There have been numerous new findings from clinical trials in recent years regarding the treatment of metastatic hormone-sensitive or castration-resistant prostate cancer. The newly approved treatment options make therapy planning and therapy sequencing more challenging. In addition, local therapy of metastatic prostate cancer is becoming increasingly important. In the new German guidelines on prostate cancer (version 6.2, October 2021), new developments in the recommendations for the treatment of mHSPC and mCRPC were implemented, and their most important resulting recommendations for the clinical practice are presented in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.